EE200300366A - Meetodid nahahaiguste ravimiseks või tõkestamiseks CD2-siduvate vahendite abil - Google Patents

Meetodid nahahaiguste ravimiseks või tõkestamiseks CD2-siduvate vahendite abil

Info

Publication number
EE200300366A
EE200300366A EEP200300366A EEP200300366A EE200300366A EE 200300366 A EE200300366 A EE 200300366A EE P200300366 A EEP200300366 A EE P200300366A EE P200300366 A EEP200300366 A EE P200300366A EE 200300366 A EE200300366 A EE 200300366A
Authority
EE
Estonia
Prior art keywords
treating
methods
binding agents
skin diseases
preventing skin
Prior art date
Application number
EEP200300366A
Other languages
English (en)
Inventor
K. Vaishnaw Akshay
D. Cooper Kevin
Shrager Daniel
S. Mccormick Thomas
Original Assignee
Biogen, Inc.
University Hospital Of Cleveland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc., University Hospital Of Cleveland filed Critical Biogen, Inc.
Publication of EE200300366A publication Critical patent/EE200300366A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2824—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200300366A 2001-02-01 2002-01-25 Meetodid nahahaiguste ravimiseks või tõkestamiseks CD2-siduvate vahendite abil EE200300366A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26596401P 2001-02-01 2001-02-01
PCT/US2002/002314 WO2002060480A1 (en) 2001-02-01 2002-01-25 Methods for treating or preventing skin disorders using cd2-binding agents

Publications (1)

Publication Number Publication Date
EE200300366A true EE200300366A (et) 2003-12-15

Family

ID=23012611

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300366A EE200300366A (et) 2001-02-01 2002-01-25 Meetodid nahahaiguste ravimiseks või tõkestamiseks CD2-siduvate vahendite abil

Country Status (22)

Country Link
US (3) US20040170635A1 (et)
EP (1) EP1409015A4 (et)
JP (1) JP2004527477A (et)
KR (1) KR20040043112A (et)
CN (1) CN1527723A (et)
AR (1) AR035079A1 (et)
BG (1) BG108020A (et)
BR (1) BR0206905A (et)
CA (1) CA2436411A1 (et)
CZ (1) CZ20032081A3 (et)
EA (1) EA200300849A1 (et)
EE (1) EE200300366A (et)
GE (1) GEP20063828B (et)
HU (1) HUP0303826A2 (et)
IS (1) IS6894A (et)
MX (1) MXPA03006919A (et)
NO (1) NO20033443L (et)
PL (1) PL368556A1 (et)
SK (1) SK9722003A3 (et)
WO (1) WO2002060480A1 (et)
YU (1) YU61203A (et)
ZA (1) ZA200305936B (et)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DE69927831T2 (de) * 1998-08-31 2006-07-20 Biogen, Inc., Cambridge Modulierung von gedächtnis-effector- zellen unter verwendung eines cd2-bindungsagens
WO2002098370A2 (en) * 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
WO2003009740A2 (en) 2001-07-24 2003-02-06 Biogen Idec Ma Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
SI1556020T1 (sl) 2002-08-12 2009-08-31 Birkir Sveinsson Uporaba spojin, ki so antagonisti CGRP, za zdravljenje psoriaze
US11517612B2 (en) 2016-11-18 2022-12-06 Nepsone Ehf Methods of treating inflammatory skin disorders
GB0307864D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
WO2005077018A2 (en) * 2004-02-06 2005-08-25 Astellas Us Llc Methods of treating skin disorders
KR20070011558A (ko) * 2004-05-04 2007-01-24 제네상스 파머슈티컬스, 아이엔씨. 일배체형 마커 및 치료에 대한 반응을 측정하기 위해 이를이용하는 방법
CA2565259A1 (en) 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
CN101113459A (zh) * 2007-07-16 2008-01-30 东莞太力生物工程有限公司 一种重组复制缺陷型病毒、含有该病毒的药物组合物及其应用
WO2011031676A2 (en) 2009-09-10 2011-03-17 Mayo Foundation For Medical Education And Research Depleting immunosuppressive monocytes within a mammal
WO2011059926A2 (en) 2009-11-10 2011-05-19 Mayo Foundation For Medical Eduction And Research Methods and materials for treating renal cell carcinoma
WO2014025198A2 (ko) * 2012-08-09 2014-02-13 주식회사 한독 Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
WO2014078272A1 (en) 2012-11-13 2014-05-22 Mayo Foundation For Medical Education And Research Methods and materials for assessing immune system profiles
US10094835B2 (en) 2013-05-09 2018-10-09 Mayo Foundation For Medical Education And Research Treating patients based on immune subtypes
CA3094756A1 (en) * 2018-03-29 2019-10-03 Pfizer Inc. Lfa3 variants and compositions and uses thereof
JP2025517363A (ja) * 2022-05-17 2025-06-05 ザ ユーエービー リサーチ ファンデーション 炎症性皮膚障害を治療または予防するための方法及び組成物
WO2024050455A2 (en) * 2022-08-31 2024-03-07 Heitmeyer Jamie Nicole Anti-rhd antibodies for treating inflammatory dermal condition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU677772B2 (en) * 1991-10-07 1997-05-08 Biogen Idec Ma Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA -3 interaction
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
US5730979A (en) * 1993-03-05 1998-03-24 Universite Catholique Delouvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
US5951983A (en) * 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
DE69927831T2 (de) * 1998-08-31 2006-07-20 Biogen, Inc., Cambridge Modulierung von gedächtnis-effector- zellen unter verwendung eines cd2-bindungsagens

Also Published As

Publication number Publication date
CZ20032081A3 (cs) 2004-01-14
ZA200305936B (en) 2005-01-26
US20070031443A1 (en) 2007-02-08
GEP20063828B (en) 2006-05-10
YU61203A (sh) 2006-05-25
HUP0303826A2 (hu) 2004-03-01
WO2002060480A1 (en) 2002-08-08
JP2004527477A (ja) 2004-09-09
KR20040043112A (ko) 2004-05-22
EA200300849A1 (ru) 2004-02-26
AR035079A1 (es) 2004-04-14
NO20033443L (no) 2003-09-30
CN1527723A (zh) 2004-09-08
SK9722003A3 (en) 2004-05-04
MXPA03006919A (es) 2004-06-02
CA2436411A1 (en) 2002-08-08
WO2002060480A9 (en) 2004-05-27
BR0206905A (pt) 2004-07-06
US20040170635A1 (en) 2004-09-02
BG108020A (bg) 2004-03-31
US20030185824A1 (en) 2003-10-02
PL368556A1 (en) 2005-04-04
IS6894A (is) 2003-07-25
NO20033443D0 (no) 2003-08-01
EP1409015A1 (en) 2004-04-21
EP1409015A4 (en) 2006-04-12

Similar Documents

Publication Publication Date Title
DE60138611D1 (de) Synergistische kombinationstherapie zur krebsbehandlung
NO20035609D0 (no) Fremgangsmåte for kontinuerlig naftabehandling
NO20035156L (no) Fremgangsmåter for brønnbehandling
BRPI0307673A2 (pt) métodos de tratar doença vascular.
IL161327A0 (en) Methods for treating ocular neovascular diseases
ZA200508427B (en) Methods for treating interleuking-6 related diseases
IL172418A0 (en) Therapeutic agents useful for treating pain
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
DK1446012T3 (da) Bakteriolytisk kombinationsterapi til behandling af tumorer
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
IL224393B (en) Compositions for treatment of huntington's disease
FIU20060389U0 (fi) Luusairauksien hoito
MXPA03003632A (es) Metodo para tratamiento de tumores usando terapia de combinacion.
DE60223576D1 (de) Hautbehandlungszusammensetzung
FI20011403L (fi) Menetelmä ja koostumukset vatsan sairauksien hoitoon
PL368556A1 (en) Methods for treating or preventing skin disorders using cd2-binding agents
EP1500401A4 (en) DRUGS FOR THE TREATMENT OF VASCULAR DISEASES
NO20063443L (no) Piperziner effektive for behandling av smerte
DE60227963D1 (de) Behandlungssystem
DE60220220D1 (de) Blutbehandlungssystem
DK1553950T3 (da) Terapeutisk behandling
EP1450820A4 (en) METHOD OF TREATING AND PREVENTING INFLAMMATORY DISEASES
DE60222664D1 (de) Hautbehandlungsmittel
DE60221068D1 (de) Gerät zur tiefenwirksamen Hauttherapie
ATE250611T1 (de) Pyranoindole zur glaukombehandlung

Legal Events

Date Code Title Description
HC1A Change of owner name